Literature DB >> 1942494

Effects of cardiac sympathetic nervous system on the stunned myocardium experimental study with 123I-metaiodobenzylguanidine.

R Nohara1, H Kambara, K Okuda, S Ono, N Tamaki, J Konishi, C Kawai.   

Abstract

123I-Metaiodobenzylguanidine (123I-MIBG) uptake in the stunned myocardium was investigated in open chest dogs. 123I-MIBG is a tracer taken up in presynaptic adrenergic vesicles and reflects the function of the myocardial sympathetic nervous system. This study revealed that in the stunned myocardium without infarct, 123I-MIBG uptake was normal up to 40 minutes of ischemia and that exogenous noradrenaline improved deteriorated regional wall motion with increased uptake of 123I-MIBG. However, uptake of 123I-MIBG per flow decreased with infarct in ischemic areas, and it showed a linear relation with regional wall motion. Thus, in the absence of infarction 123I-MIBG is a tracer to differentiate stunning from more severe ischemia with persistent wall motion abnormality. Normal uptake and storage of 123I-MIBG in the stunned condition suggests that catecholamine release or second effector mechanism may relate to the mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942494     DOI: 10.1253/jcj.55.893

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  3 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  123I-MIBG myocardial imaging in hypertensive patients: abnormality progresses with left ventricular hypertrophy.

Authors:  I Mitani; S Sumita; N Takahashi; H Ochiai; M Ishii
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

3.  How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US.

Authors:  Mark I Travin; Ichiro Matsunari; Gregory S Thomas; Kenichi Nakajima; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2018-09-03       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.